Incidence of cancer in patients with ulcerative colitis 30 years after diagnosis (the IBSEN study)

Figures & data

Figure 1. Cumulative incidence for cancer and mortality, stratified by sex, from the time of diagnosis. (a) Cumulative incidence of cancer and of death in women. (b) Cumulative incidence of cancer and of death in men.

Table 1. Demographic and clinical characteristics of the IBSEN study population.

	Number, at diagnosis (%)	Number with incident cancer (%)
Males	267 (51.4)	47 (56.6)
Females	252 (48.6)	36 (43.4)
Age < 17	20 (3.9)	2 (2.4)
Age 17–39	269 (51.8)	24 (28.9)
Age ≥ 40	230 (44.3)	57 (68.6)
Proctitis	171 (32.9)	20 (23.2)
Left-sided colitis	182 (35.1)	31 (36)
Pancolitis	166 (32.0)	32 (37.2)
Smoker	68 (13.3)
Ex-smoker	156 (30.1)
Thiopurine prescription (%)
User	48 (9.2)	11 (13.3)
Non-user	438 (84.4)	68 (81.9)
Unknown	33 (6.4)	4 (4.8)

Table 2. Hazard ratios (HR) of the most frequent cancer types in patients compared to controls.

	UC females		UC males		UC
	HR	95% CI	HR	95% CI	HR	95% CI
Cancer (first occurrence)	0.90	0.62–1.30	1.12	0.80–1.56	1.01	0.79–1.29
Colorectal cancer (C18–C20, C21.8)	1.17	0.49–2.76	1.75	0.76–4.04	1.37	0.75–2.47
Hematologic malignancies (C81-C96)	0.81	0.23–2.89	3.48	1.55–7.82	2.08	1.08–4.00

Table 3. Distribution of colorectal cancer (CRC) SEER stages in patients and controls.

CRC SEER stage (n)	Distant	Regional	Localized	Unknown
Patients with UC	0	9	6	1
Controls	12	34	8	9

Table 4. Number of observed incident cancer diagnoses and standardized incidence ratios (SIR) of the common cancer types in patients.

ICD-10	Cancer type	Females (n)	Males (n)	SIR Females	95% CI	SIR Males	95% CI	SIR UC	95% CI
C00-96	All cancer types	42	57	1.05	0.75–1.39	1.03	0.78–1.32	1.04	0.84–1.25
C15–26	Digestive organs	13	14	1.60	0.85–2.58	1.25	0.68–1.98	1.40	0.92–1.70
C18–C20	Colorectal	8	8	1.52	0.65–2.73	1.19	0.52–2.15	1.33	0.76–2.06
C23–C24	Hepatobiliary	2	3	8.27	1.00–23.05	11.25	2.32–27.1	9.84	3.19–20.15
C30–34, C38	Respiratory and intrathoracic organs	1	7	0.26	0.001–0.98	1.08	0.44–2.02	0.78	0.34–1.41
C43	Malignant melanoma	5	3	2.09	0.68–4.28	1.03	0.21–2.47	1.51	0.65–2.72
C44	Non-melanoma skin cancer	2	5	0.88	0.11–4.25	1.46	0.47–2.99	1.23	0.49–2.29
C50	Breast	12	0	1.27	0.66–2.09	0.00	–	1.26	0.65–2.07
C51–58	Female genital organs	1	0	0.20	0.00–0.72			0.20	0.00–0.72
C60–63	Male genital organs	0	8			0.50	0.22–0.90	0.50	0.22–0.90
C64–68	Urinary tract	3	3	1.64	0.34–3.95	0.55	0.11–1.31	0.82	0.30–1.59
C73	Thyroid gland	1	1	1.87	0.05–6.91	4.05	0.10–14.95	2.56	0.31–7.14
C81–96	Hematologic	3	11	0.95	0.20–2.30	2.31	1.15–3.87	1.77	0.97–2.81

Table 5. Number of incident biliary tract cancers in patients with ulcerative colitis (UC), patients with primary sclerosing cholangitis (PSC), and in controls.

	Biliary tract cancer C22.1, C23, C24 (n)	Without biliary tract cancer (n)
Patients with UC without PSC	2	496
Patients with UC and PSC	3	18
Controls	7	2588

Data availability statement

The data underlying this article cannot be shared publicly due to the restrictions imposed by the ethics committee, the registers, and the national legal framework.